Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.

JR, Teerlink; M, Metra; GS, Filippatos; BA, Davison; J, Bartunek; A, Terzic; BJ, Gersh; TJ, Povsic; TD, Henry; B, Alexandre; C, Homsy; C, Edwards; A, Seron; W, Wijns; G, Cotter

doi:10.1002/ejhf.898

Public

Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study.

Shared by NobleBlocks on May 31, 2017 • 12:00 AM UTC

Authors:

Teerlink JR

Metra M

Filippatos GS

Abstract

Aims Left ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone-marrow-derived, lineage-directed, autologous cardiopoietic mesenchymal stem cells (C3BS-CQR-1)...

Subject

Heart Failure

Stem Cells

Remodelling

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!